Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJul 24, 2026
DataAggregated Company Financials
Companies20
  • 7D-4.1%
  • 3M18.5%
  • 1Y-24.5%
  • YTD-5.0%

Over the last 7 days, the Healthcare industry has dropped 2.6%, driven by Novo Nordisk declining 3.3%. The industry has fallen 23% in the last year. Looking forward, earnings are forecast to grow by 1.9% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 24 Jul 2026DKK 1.8tDKK 469.5bDKK 147.2b20.1x12.6x3.9x
Sun, 21 Jun 2026DKK 1.7tDKK 469.0bDKK 147.1b19.6x11.6x3.6x
Tue, 19 May 2026DKK 1.7tDKK 468.6bDKK 147.0b20.3x11.5x3.6x
Thu, 16 Apr 2026DKK 1.5tDKK 447.1bDKK 129.9b19x11.9x3.4x
Sat, 14 Mar 2026DKK 1.5tDKK 448.1bDKK 130.1b16.8x11.6x3.4x
Mon, 09 Feb 2026DKK 1.8tDKK 448.2bDKK 134.9b16.7x13.1x3.9x
Wed, 07 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.9x15.5x4.7x
Fri, 05 Dec 2025DKK 1.9tDKK 454.0bDKK 136.9b17x13.6x4.1x
Sun, 02 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Tue, 30 Sep 2025DKK 2.0tDKK 447.4bDKK 141.7b18x14.4x4.6x
Thu, 28 Aug 2025DKK 2.1tDKK 447.6bDKK 141.8b24.3x14.5x4.6x
Sat, 26 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Mon, 23 Jun 2025DKK 2.6tDKK 423.5bDKK 124.6b30.4x20.6x6.1x
Wed, 21 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Fri, 18 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Sun, 16 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Tue, 11 Feb 2025DKK 3.3tDKK 408.3bDKK 118.3b28.4x27.6x8x
Thu, 09 Jan 2025DKK 3.3tDKK 387.5bDKK 111.3b29.9x29.6x8.5x
Sat, 07 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Mon, 04 Nov 2024DKK 4.0tDKK 372.2bDKK 107.2b34.5x37.1x10.7x
Wed, 02 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Fri, 30 Aug 2024DKK 4.7tDKK 371.8bDKK 107.1b33.8x44.1x12.7x
Sun, 28 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Tue, 25 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b34.8x46.7x14x
Thu, 23 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.9x44.1x13.2x
Sat, 20 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b32.8x44.3x12.9x
Mon, 18 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.3x46.5x13.6x
Wed, 14 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.4x43.3x12.5x
Fri, 12 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.8x42.1x11.8x
Sun, 10 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Tue, 07 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.2x40x11.3x
Thu, 05 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b32.5x40.9x11x
Sat, 02 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Mon, 31 Jul 2023DKK 2.9tDKK 287.2bDKK 75.5b37.2x38.5x10.1x
Price to Earnings Ratio

38.5x


Total Market Cap: DKK 2.9tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 28.8x.
  • The 3-year average PS ratio of 8.3x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-4.01%
Healthcare-4.09%
Healthcare Services2.42%
Biotech-0.013%
Life Sciences-2.00%
Medical Equipment-4.02%
Pharma-4.50%
Healthtech-4.67%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.9x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.2% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.90k0.7%
+DKK 828.8m		26.7%PE21.7x
HLUN B H. LundbeckDKK 42.461.5%
+DKK 614.6m		20.6%PE11.3x
EMBLA Embla Medical hfDKK 26.801.1%
+DKK 116.4m		-16.5%PE18.5x
BIOPOR BioPortoDKK 1.2118.7%
+DKK 94.1m		-11.4%PS14.8x
GUBRA GubraDKK 353.001.1%
+DKK 62.1m		-15.9%PE3.4x

Latest News

HLUN B
DKK 42.46
H. Lundbeck
7D
1.5%
1Y
20.6%
GMAB
DKK 1,904.00
Genmab
7D
0.7%
1Y
26.7%
EMBLA
DKK 26.80
Embla Medical hf
7D
1.1%
1Y
-16.5%
Analysis Article • 10h

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
NOVO B
DKK 320.30
Novo Nordisk
7D
-4.6%
1Y
-28.4%
ZEAL
DKK 296.90
Zealand Pharma
7D
-0.5%
1Y
-23.3%
Narrative Update • Jul 23

ZEAL: Future Returns Will Hinge On Obesity Pipeline Execution Timing

The updated analyst price target for Zealand Pharma moves to DKK 300 from DKK 400. This reflects a more cautious stance as analysts point to fewer near term catalysts, lower peak sales expectations for petrelintide and survodutide, and a higher assumed discount rate and future P/E in their models.
DEMANT
DKK 269.20
Demant
7D
-5.4%
1Y
-3.5%
Narrative Update • Jul 21

DEMANT: Growth Inflection Expectations In European Medtech Set To Drive Upside

The analyst price target for Demant has been raised from DKK 300 to DKK 310. Analysts point to modest adjustments in fair value, discount rate, revenue growth assumptions and future P/E expectations, alongside mixed recent rating changes that reflect both perceived growth potential and valuation constraints.
AMBU B
DKK 67.50
Ambu
7D
-4.5%
1Y
-34.0%
Narrative Update • Jul 15

AMBU B: Margin Resilience And Competitive Response Are Expected To Drive Future Upside

The analyst price target for Ambu has been cut from DKK 138.0 to DKK 116.4, as analysts adopt more cautious assumptions around competition, growth, margins, discount rate and future P/E following recent bearish research updates. Analyst Commentary Recent research on Ambu has leaned more cautious, with some price targets and ratings adjusted to reflect concerns about competition and the near term outlook.
COLO B
DKK 398.80
Coloplast
7D
-3.7%
1Y
-35.7%
Narrative Update • Jul 15

COLO B: Recent P/E Reset Will Create Upside Opportunity

Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
BAVA
DKK 176.60
Bavarian Nordic
7D
-5.8%
1Y
-24.2%
ALK B
DKK 228.40
ALK-Abelló
7D
-5.9%
1Y
15.6%
Narrative Update • Jul 10

ALK B: Allergy Immunotherapy Leadership Will Drive Future Earnings Reassessment

Analysts have raised their price target on ALK-Abelló from DKK 185 to DKK 285, citing the company's position as a global leader in allergy immunotherapy and recent Street research that supports this view. What’s in the News for ALK-Abelló MHRA in the UK granted marketing authorisation for EURneffy 1 mg, the first needle-free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 kg to less than 30 kg.
CHEMM
DKK 405.00
ChemoMetec
7D
-4.4%
1Y
-21.7%
GUBRA
DKK 353.00
Gubra
7D
1.1%
1Y
-15.9%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
SMSMED
DKK 2.96
Scandinavian Medical Solutions
7D
2.4%
1Y
-37.4%
BIOPOR
DKK 1.21
BioPorto
7D
18.7%
1Y
-11.4%
PEG
DKK 0.085
Pharma Equity Group
7D
3.7%
1Y
-28.3%
STRAP
DKK 700.00
Strategic Partners
7D
9.4%
1Y
-35.2%